Mutations of EP300 were observed in 10% of DLBCL.329 In PTCL-NOS, CREBBP and EP300 are mutated in 4% and 8% of patients, respectively.328 In NKTCL, EP300 is mutated in approximately 3.8% of patients.243. Here, EP300 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.